The impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study
Clinical Infectious Diseases
Jan 11, 2018
van Deursen AMM, et al. - Researchers here examined the direct effects of the 13-valent pneumococcal conjugate vaccine (PCV13) in community dwelling older adults as part of the randomized controlled Community Acquired Pneumonia immunization Trial in Adults (CAPiTA). In this work, a single dose of PCV13 seemed to elicit a small and temporary reduction in vaccine-type (VT)-carriage at 6 months post-vaccination in community-dwelling adults of 65 years and older. They recognized neither replacement by non-vaccine serotypes nor impact on other nasopharyngeal bacteria.
Go to Original
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In